- Home
- CIA vs PBYI Comparison
CIA vs PBYI Comparison
Compare CIA & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIA
- PBYI
- Stock Information
- Founded
- CIA 1969
- PBYI 2010
- Country
- CIA United States
- PBYI United States
- Employees
- CIA N/A
- PBYI N/A
- Industry
- CIA Life Insurance
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- CIA Finance
- PBYI Health Care
- Exchange
- CIA Nasdaq
- PBYI Nasdaq
- Market Cap
- CIA 212.6M
- PBYI 175.7M
- IPO Year
- CIA N/A
- PBYI N/A
- Fundamental
- Price
- CIA $3.30
- PBYI $3.46
- Analyst Decision
- CIA
- PBYI Strong Buy
- Analyst Count
- CIA 0
- PBYI 1
- Target Price
- CIA N/A
- PBYI $7.00
- AVG Volume (30 Days)
- CIA 498.6K
- PBYI 314.4K
- Earning Date
- CIA 08-05-2025
- PBYI 07-31-2025
- Dividend Yield
- CIA N/A
- PBYI N/A
- EPS Growth
- CIA N/A
- PBYI 143.51
- EPS
- CIA 0.17
- PBYI 0.77
- Revenue
- CIA $242,941,000.00
- PBYI $232,709,000.00
- Revenue This Year
- CIA $3.89
- PBYI N/A
- Revenue Next Year
- CIA $6.08
- PBYI N/A
- P/E Ratio
- CIA $19.30
- PBYI $4.47
- Revenue Growth
- CIA 0.19
- PBYI 2.68
- 52 Week Low
- CIA $2.33
- PBYI $2.23
- 52 Week High
- CIA $5.95
- PBYI $4.13
- Technical
- Relative Strength Index (RSI)
- CIA 39.32
- PBYI 50.88
- Support Level
- CIA $3.45
- PBYI $3.36
- Resistance Level
- CIA $3.69
- PBYI $3.68
- Average True Range (ATR)
- CIA 0.14
- PBYI 0.12
- MACD
- CIA -0.01
- PBYI -0.01
- Stochastic Oscillator
- CIA 8.33
- PBYI 48.84
About CIA Citizens Inc. ($1.00 Par)
Citizens Inc is an insurance holding company serving the life insurance needs of individuals in the United States. The company provides insurance benefits to residents in thirty two U.S. states and more than seventy countries through its insurance subsidiaries. The company operates in two business segments namely the Life Insurance segment and the Home Service Insurance segment. The company majority generates revenues from Life Insurance segment. Company operates in USA, Columbia, Taiwan, Venezuela, Ecuador, Argentina, and Others.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.